Suhayya Batool

Suhayya Batool

Auto-generated profile, based on publicly available information

Suhayya Batool

Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SBSyed Mohsin Raza Mbbs Bukhari
Syed Mohsin Raza Mbbs Bukhari
SBSuhayya Mbbs Btool
Suhayya Mbbs Btool
JAJalil Mbbs Abbas
Jalil Mbbs Abbas
AHArif Mbbs Hussain
Arif Mbbs Hussain
HMHassan Mbbs Mehdi
Hassan Mbbs Mehdi
MRMohsin Mbbs Raza
Mohsin Mbbs Raza
An abstract is unavailable. This article is available as a PDF only.


28 October 2025 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
SBSuhayya Batool
Suhayya Batool
MAMinahil Amjad
Minahil Amjad
AMArfa Madni
Arfa Madni


1 August 2026 in Retina
Verified
Journal Article
Closed access
SBSuhayya Batool
Suhayya Batool
Was not provided for this article.

31 October 2026 in Clinical Cardiology
Verified
Journal Article
Open access
ACAmarelle Chamoun
Amarelle Chamoun
TFTalha Farooq
Talha Farooq
SBSuhayya Batool
Suhayya Batool
STSadia Tameez‐Ud—Din
Sadia Tameez‐Ud—Din
MYMuhammad Yousaf
Muhammad Yousaf
KKKamil Ahmad Kamil
Kamil Ahmad Kamil
Background: Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all global heart failure cases. Historically viewed as a left‐centric diastolic disorder, emerging evidence identifies right ventricular (RV) dysfunction and impaired ventriculo‐arterial (RV‐PA) coupling as central drivers of exercise intolerance, functional decline, and adverse clinical outcomes. Objectives: This review synthesizes current evidence on the pathophysiological mechanisms, advanced diagnostic modalities, prognostic implications, and phenotype‐specific therapies for RV dysfunction in HFpEF, advocating for a transition to systematic biventricular evaluation. Methods: A structured, PRISMA‐informed search of PubMed and Scopus (2015–2024) identified 74 eligible studies evaluating RV structure, function, and hemodynamics in HFpEF cohorts. Results: RV dysfunction is prevalent in 19% to 33% of HFpEF patients and independently predicts all‐cause mortality and heart failure hospitalizations. Key pathophysiological drivers include post‐capillary pulmonary hypertension, impaired RV lusitropy, systemic inflammation, and inter‐ventricular dependence. Non‐invasive markers notably speckle‐tracking echocardiography, 4D‐flow cardiac magnetic resonance (CMR), and the TAPSE/PASP ratio enable early identification of subclinical RV‐PA uncoupling. While traditional heart failure therapies show limited efficacy, emerging options including SGLT2 inhibitors, interatrial shunt devices, GLP‐1 receptor agonists, and targeted pulmonary vasodilators demonstrate potential to preserve RV strain and restore hemodynamics across distinct clinical phenotypes. Conclusions: RV dysfunction is a major prognostic marker in HFpEF. Routine inclusion of RV‐PA coupling indices in diagnostic and risk‐stratification algorithms is essential to guide precision‐based, phenotype‐guided management and improve clinical trajectories.